Smallpox vaccines for biodefense: need and feasibility

@article{Artenstein2008SmallpoxVF,
  title={Smallpox vaccines for biodefense: need and feasibility},
  author={A. Artenstein and J. Grabenstein},
  journal={Expert Review of Vaccines},
  year={2008},
  volume={7},
  pages={1225 - 1237}
}
Smallpox, eradicated as a cause of natural disease through an intensive global effort in the later part of the 20th Century, has resurfaced as a possible agent of bioterrorism. For this reason, there is renewed interest in smallpox vaccines. Live vaccinia virus, an orthopoxvirus related to smallpox, has a long and successful clinical track record as an effective smallpox vaccine; however, its use is associated with uncommon yet serious adverse events. This has led to a surge of recent research… Expand
Smallpox vaccines: New formulations and revised strategies for vaccination
TLDR
The history of smallpox vaccines and recent achievements in the development of highly efficacious and safer vaccines and vaccine applications are reviewed and assessment of adequate animal models to study pathogenesis and protective immunity is reviewed. Expand
Smallpox vaccines for biodefense.
TLDR
Given the ongoing concerns regarding the use of variola as a biological weapon, this review will focus on the licensed vaccines as well as current research into next-generation vaccines to protect against smallpox and other poxviruses. Expand
The immunology of smallpox vaccines.
TLDR
Recent studies have focused on establishing the longevity of poxvirus-specific immunity, defining key immune epitopes targeted by T and B cells, developing subunit-based vaccines, and developing genotypic and phenotypic immune response profiles that predict either vaccine response or adverse events following immunization. Expand
Development of an attenuated smallpox vaccine candidate: The KVAC103 strain.
TLDR
A cell culture-based highly attenuated third-generation smallpox vaccine candidate KVAC103 strain is developed by 103 serial passages of the Lancy-Vaxina strain derived from the Lister in Vero cells due to its enhanced safety and efficacy. Expand
Smallpox and bioterrorism
TLDR
A public-health response to smallpox as using for bioterrorism is described, with great concern that smallpox is an excellent candidate for use as a terrorist weapon. Expand
Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.
TLDR
It is demonstrated that virus-like replicon particles (VRPs) expressing the vaccinia virus A33R, B5R, A27L, and L1R genes elicited protective immunity in mice comparable to vaccination with live-vaccinia virus, and revealed that a single-boost VRP smallpox vaccine shows promise as a safe alternative to the currently licensed live- Vaccinia virusSmallpox vaccine. Expand
Safe and Effective Smallpox Vaccine Development Using DNA Vaccines and In vivo Electroporation
Few viruses have elicited more fear of its potential as a tool of bioterrorism than smallpox. In the post-9/11 “Amerithrax” environment, the threat of an intentional release of smallpox has led toExpand
Co-administration of tecovirimat and ACAM2000™ in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge.
TLDR
In studies presented here, monkeys were vaccinated with the ACAM2000TM live attenuated smallpox vaccine and concomitantly treated with tecovirimat or placebo, suggesting that TPOXX may affect the immunogenicity of ACAM 2000 if administered concomittantly. Expand
Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.
TLDR
Data suggest that, with the exception of individuals with irreversible, combined CD4(+) and CD8(+) T-cell deficiency, ST-246 co-administered at the time of vaccination may help reduce vaccine reactogenicity--even in those lacking humoral immunity--without impeding the induction of protective immunity. Expand
Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults.
TLDR
LC16m8 generates neutralizing antibody titers to multiple poxviruses, including vaccinia, monkeypox, and variola major, and broad T-cell responses, indicating that LC 16m8 may have efficacy in protecting individuals from smallpox. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 131 REFERENCES
Modified vaccinia Ankara: potential as an alternative smallpox vaccine.
TLDR
Alternative approaches to maintaining immunity to smallpox through vaccination with attenuated poxviruses are reviewed, and modified vaccinia Ankara (MVA) is suggested as a leading candidate for an alternative smallpox vaccine. Expand
LC16m8: An attenuated smallpox vaccine
TLDR
The history and available scientific literature regarding LC16m8, an attenuated, replicating smallpox vaccine derived from the Lister strain of vaccinia, is reviewed and comparisons to other smallpox vaccines are provided. Expand
New generation smallpox vaccines: a review of preclinical and clinical data
TLDR
Substantial animal and limited human data suggest that selected second and third generation smallpox vaccines, specifically tissue‐cultured vaccinia virus and replication‐competent, highly attenuated Vaccinia virus possess immunogenicity and surrogate efficacy profiles similar to those of first generation New York City Board of Health and Lister vaccines. Expand
An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies.
TLDR
Recently accumulated data on the assessment of new smallpox vaccine candidates are reviewed and their role in possible vaccination policies is discussed. Expand
Smallpox vaccines: Past, present, and future.
TLDR
Although motivated by the threat of bioterrorism, the hope is for new poxvirus vaccines to have their greatest utility against other pathogenic orthopoxviruses such as monkeypox and for the development of recombinant poxVirus-based vectors to treat and prevent other diseases. Expand
Smallpox vaccine and its stockpile in 2005.
  • I. Arita
  • Medicine
  • The Lancet. Infectious diseases
  • 2005
Smallpox vaccine was the most important tool in the successful eradication of smallpox. In 1980, this achievement made it possible for all nations to cease smallpox vaccination. However, the threatExpand
Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge.
TLDR
It is shown that LC16m8 and Dryvax elicit comparable humoral immune responses after a single vaccination and equivalently protect against lethal poxvirus disease. Expand
A novel, cell culture-derived smallpox vaccine in vaccinia-naive adults.
TLDR
Whether a clonal smallpox vaccine manufactured in cell culture, ACAM2000, is equivalent to the standard calf-lymph vaccine, Dryvax, in terms of cutaneous response rate, antibody responses and safety is determined. Expand
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox
TLDR
The highly attenuated modified vaccinia virus Ankara (MVA) with the licensed Dryvax vaccine in a monkey model is compared and unimmunized animals developed more than 500 pustular skin lesions and became gravely ill or died, whereas vaccinated animals were healthy and asymptomatic. Expand
Smallpox DNA Vaccine Protects Nonhuman Primates against Lethal Monkeypox
TLDR
This is the first demonstration that a subunit vaccine approach to smallpox-monkeypox immunization is feasible and it is demonstrated that rhesus macaques vaccinated with a DNA vaccine consisting of four vaccinia virus genes were protected from severe disease after an otherwise lethal challenge with monkeypox virus. Expand
...
1
2
3
4
5
...